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Background: The changing pattern of hepatitis C virus (HCV) infection could have a sig-
niﬁcant impact on future medical prevention practices and therapies. 
Objectives: The purpose of this study was to describe the changing pattern of HCV infec-
tion in southwest China using clinical epidemiology, and to assess the association be-
tween the genotypes distribution and certain potential risk factors.
Patients and Methods: A retrospective analysis which included 1208 subjects with 
chronic HCV registered at the Southwest Hospital (Chongqing, Southwest China) was 
performed. The information was reviewed and the data collected from clinical records 
and short telephone interviews when necessary. HCV genotypes were determined by 
nucleotide sequencing of the CE1 regions followed by phylogenic analysis with the pub-
lished HCV genotype. HCV genotype distribution was analyzed according to the patients’ 
age, gender, risk exposure, and the initial risk exposure.
Results: Among the 1 208 patients, the HCV subtype 1b was the most prevalent (32.9%), 
followed by subtype 3b (18.9%), 6a (18.0%), 3a (12.8%) and 2a (10.4%), while subtypes 1a and 
6k accounted for cases of HCV infection in only 9 and 3 cases respectively. Individuals 
older than 40 years were mainly infected with subtypes 1b and 2a, whereas younger 
patients were predominantly infected with genotypes 3 and 6. Subtypes 1b and 2a were 
observed more frequently among 44.4% and 16.0% patients respectively, with a history 
of invasive operations. Subtypes 3b and 6a constituted the majority of HCV infections 
among intravenous drug users (IDUs) (28.7% and 34.9%, respectively). A signiﬁcant diﬀer-
ence (P < 0.001) was observed between the HCV genotype distributions, according to the 
potential route of infection.
Conclusion: In southwest China, the most common remaining subtype is the 1b gen-
otype, but this has declined signiﬁcantly among young patients. This is followed by 
subtype 3b and 6a which has increased signiﬁcantly, especially among young patients. 
The distribution of such genotypes was also variable according to gender and age. The 
changing pattern of HCV infection was associated with changes in the modes of HCV ac-
quisition, which raises an alarm signal concerning the major steps that need to be taken 
in order to reduce such infections in southwest China. 
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 Implication for health policy/practice/research/medical education:
This article investigates the changing pattern of clinical Epidemiology on hepatitis C virus infection in Southwest China. This has 
an important implication for those who are involved in  medical prevention and therapy to chronic hepatitis C.
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1. Background
  The hepatitis C virus (HCV) is a major cause of liver dis-
ease worldwide and will be a potential source of substan-
tial cases of morbidity and mortality in the future (1). It is 
estimated that approximately 130–210 million individu-
als, i.e. 3% of the world’s population, are chronically in-
fected with the HCV (2). The prevalence varies markedly 
from one geographical area to another and within the 
population assessed (3). In Western Europe, HCV preva-
lence rates range from 0.4% to 3%. It is higher in Eastern 
Europe and the Middle East, in countries such as Egypt 
(15%), Romania (6%), Pakistan (4.7%) and in Ukraine (4.0%) 
(4, 5). There is a wide range of prevalence estimates 
among developing countries, and generally less data 
available to validate assumptions about the burden of 
disease, than in the developed world (6, 7). Studying the 
epidemiology of HCV infections plays an important role 
in the methods of its prevention (8, 9). HCV genotypes/
subtypes are clinically very important as diﬀerent geno-
types are relevant to epidemiological questions, vaccine 
development, and the clinical management of chronic 
HCV infection (10, 11). HCV genotypes have also been 
showed to have unique patterns of geographic distribu-
tion and to be a major tool in HCV epidemiological stud-
ies (12). HCV genotypes 1, 2 and 3 are commonly distribut-
ed all over the world and their relative prevalence varies 
from one geographic area to another, while genotypes 
4, 5, and 6 are generally found only in certain areas. For 
example, HCV subtypes 1a and 1b are the most common 
genotypes in the United States (13), Europe (14-17) and Ja-
pan (18). HCV-3 (predominantly 3a) is the most prevalent 
genotype circulating in India (19) and Pakistan (20). HCV 
genotype 4 appears to be more prevalent in North Africa 
(21) and the Middle East (22). HCV genotypes 5 and 6 seem 
to be conﬁned to South Africa (23) and Hong Kong (24), 
respectively.
The distribution of HCV genotypes varies signiﬁcantly 
according to changing modes of HCV acquisition (25). 
Therefore, the epidemiological studies of HCV genotypes 
in diﬀerent risk populations may provide a better under-
standing into the nature of HCV infection and its spread. 
The epidemiological patterns of HCV vary greatly among 
the diﬀerent countries and even among the regions of 
the same country. The epidemiology varies geographi-
cally and temporally due to its distribution and the 
evolution of risk factors (26). The epidemiology of HCV 
is highly associated with certain risk groups such as: re-
cipients of blood and/or blood products, injecting drug 
use (IDU), sexual transmission, inadequate sterilizing of 
medical equipment, body piercing and the sharing of ra-
zors and other personal items which are contaminated 
with HCV (20). With the implementation of mandatory 
HCV screening of blood and blood products in the early 
1990s, the number of post-transfusion infections had al-
ready decreased dramatically, while IDU has accelerated 
in China (27-29). In China, previous studies have indicat-
ed that the most prevalent HCV subtype was 1b, followed 
by 2a (30, 31), while recently studies have shown new 
trends of HCV infection in some regions of China (32, 33). 
Thus, it is important to investigate the clinical epidemio-
logical shift in the prevalence of the predominant HCV 
genotype and the signiﬁcance of the changes. 
2. Objectives
An epidemiological study concerning HCV genotypic 
distribution in the southwest region of China has been 
reported in a small population in this region (34). How-
ever, studies on the changing pattern of clinical epidemi-
ology on hepatitis C virus infections in southwest China 
are scarce and the HCV genotype distribution in this re-
gion needs to be determined in larger sample studies. 
The objectives of this study were to describe the clinical 
epidemiological changing patterns of HCV infection in 
southwest China, and to determine whether there are 
any associations between HCV genotypes and the mode 
of acquisition, and how this could assist in the preven-
tion of such virus infections among the people of south-
west China.
  3. Patients and Methods
3.1. Study Participants
Individuals with HCV infection who were registered 
and followed up at   the Southwest Hospital (  Chongqing, 
Southwest China) from January 2004 and June 2011 were 
included for the primary selection. All patients ﬁnally 
enrolled in the study had anti-HCV positivity and detect-
able serum HCV RNA for at least 6 months. Information 
on these patients were obtained mainly from clinical 
records retrospectively and short telephone interviews 
with a structured questionnaire when necessary. The 
study was designed to collect the data and extract infor-
mation from each patient including; age, gender, year 
of diagnosis and risk factors for HCV. The risk exposures 
considered in this study were; transfusion of blood or 
blood products, blood plasma donation, hemodialysis, 
tattoos, acupuncture therapy, injecting drug use (IDU), 
high-risk sexual practices, occupational exposure, sur-
gical operations, intra-family transmission, etc. Those 
patients who denied any risk factors were assigned to a 
group labeled unknown. Patients with more than one 
risk factor were assigned to a single risk group according 
to the hierarchy described above.   There was prospective 
informed consent and interviews as well as prospective 
HCV genotyping in this retrospective study. All subjects 
provided informed consent to participate in the study, 
as approved by the ethical committee of the Southwest 
Hospital, Chongqing, China.
3.2. Laboratory and Clinical Evaluation of HCV Infection
Serum samples were collected from the patients and 
were tested positive for   HCV antibody using the 3rd gen-
eration commercial Enzyme Linked Immunosorbent As-
say Kits, INNO-LIA HCV Ab III update Immunoassay (LIA, 
Innogenetics S.r.l., Gent, Belgium). Such an immunoassay 
is known to have a high speciﬁcity and sensitivity (over 198 Hepat Mon. 2012
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99%), with minimal or no limitation in detecting the HCV 
antibody. The HCV RNA load was tested on the seroreac-
tive samples using quantitative real-time PCR   (ABI Prism 
7000  , Applied Biosystems, Foster City, CA). The diagnos-
tic criteria for the HCV were based on the combination 
of; clinical history, physical examination, imaging and 
laboratory data and/or histology. Diagnosis of cirrhosis 
was made by positive histological ﬁndings or an elevated 
clinical/laboratory data combined with at least one posi-
tive image (ultrasonography, computed tomography, 
magnetic resonance imaging and/or ﬁbroscan).
3.3. HCV Genotyping
  HCV RNA was extracted using the commercial extrac-
tion kit QIAamp Viral RNA Mini Kits (Qiagen, Shanghai, 
China). Extracted RNA was used for reverse transcription 
(RT) followed by nested PCR with two sets of conserved 
primers deduced from the core-envelope 1 (CE1) region of 
the HCV genome as described in previous research (35). 
Both the RT and nested PCR were performed in a MyCy-
cler Thermal Cycler (BIO-RAD, Hercules, CA, USA). The am-
plicon fragment was 474bp in length. Genotypes of all of 
the samples were determined by nucleotide sequencing 
of the CE1 region followed by phylogenic analysis with 
the published HCV genotype references in GenBank. 
Electrophoresis of the sequenced products and analysis 
of the electrophoregrams were performed with the use 
of sequenator DNA ABI Prism 3730 (Applied Biosystem  s, 
Foster City, CA). Phylogenic comparison to reference se-
quences of particular subtypes was performed with the 
Viral Genotyping Tool on the NCBI website.
3.4. Statistical Analysis
  Statistical analysis was performed using SPSS software 
(version 9.0; SPSS Inc, Chicago, IL). A 2-sided p-value less 
than 0.05 was considered to be signiﬁcant. χ2 tests were 
performed to examine the diﬀerences in the distribu-
tion of categorical variables. Quantitative variables were 
expressed as mean ± standard deviation and were com-
pared by a Student’s t-test. Diﬀerences in the proportion 
of qualitative variables were tested with non-parametric 
tests, Yates correlation. A multivariate analysis was con-
ducted using logistic regression in order to verify which 
variables statistically had an inﬂuence on the HCV infec-
tion. 
4. Results
  4.1. Clinical Epidemiological Characteristics of Study 
Population
A total of 1 208 patients were enrolled in this study from 
diﬀerent geographical provinces in   southwest China. 
All patients are native residents of southwest China and 
the   majority of them were from Chongqing (n = 745; 
61.7%), followed by Sichuan (n = 256; 21.2%) and Guizhou 
(n = 169; 13.9%), while the others came from other south-
west provinces (Yunnan, Guangxi and Xizang). The ages 
of the patients in the study ranged from 16 to 88 years 
with a mean age   (±SD) of 38.5 ± 11.5 years.   Of these, 707 
patients (58.5%) were male and 501 patients (41.5%) were 
female.   Out of a total of 1 208 cases, the HCV genotype 
was available for 1 137 patients (94.1%) and  non-detectable 
in 71 subjects (5.9%)  .   Genotypes 1, 2, 3, and 6 were found 
in our population. HCV subtypes 1b was the most preva-
lent subtype (n = 398, 32.9%),   followed by subtype 3b (n = 
228, 18.9%), 6a (n = 218, 18.0%), 3a (n = 155, 12.8%) and 2a (n 
= 126, 10.4%), while   subtype 1a and 6k accounted for HCV 
infection in only 9 (0.7%) and 3 (0.3%) individuals respec-
tively. No diﬀerences were found in serum HCV-RNA lev-
els among the HCV genotypes; mean levels of HCV-RNA 
(copies/ml) in log10 were: 5.9 ± 1.4 for genotype 1, 6.2 ± 
0.8 for genotype 2, and 5.7 ± 0.6 for genotype 3, and 6.4 ± 
1.5 for genotype 6. Furthermore, the main HCV genotype 
distribution diﬀered signiﬁcantly by gender. Subtype 3a 
 (men/women: 15.9% vs. 7.8%, P = 0.0003), 3b (21.6% vs. 14.4%, 
P = 0.009) and 6a (20.3% vs. 14.37%, P = 0.03) were more 
frequent in men than in women.   In contrast, subtype 1b 
(men/women: 29.11% vs. 39.22%,   P = 0.011) and 2a (8.013% 
vs. 14.4%, P = 0.002) were more frequent in women than 
in men. Although eﬀorts were made to obtain   the   poten-
tial route of infection for each patient in our study, the 
mode of HCV acquisition in 210 (17.4%) cases remained 
unknown. Of the 1 208 patients, 406 (33.6%) had a his-
tory of transfusion of blood and/or blood products, 352 
(29.4%) had a history of IDU, 144 (11.9%) had a history of 
invasive operation (hemodialysis, tattoos, acupuncture 
therapy, dental procedures, occupational exposure, etc); 
96 (7.9%) had a history of high-risk sexual practices (his-
tory of promiscuity, infected from family members).   No 
signiﬁcant diﬀerences were observed between the gen-
ders of the sex-related (P = 0.364) and source-unknown 
chronic hepatitis C  (P = 0.228). However,  there were more 
frequent cases in women than in men (P ≤ 0.001) for 
transfusion-related (men/women: 29.24% vs. 40.74%, P = 
0.004) and operation-related chronic hepatitis C (CHC  ) 
 (men/women:  9.48%  vs. 16.91%, P = 0.003). In contrast, 
IDU’s   were more frequently male than female (men/
women: 36.58% vs. 16.99%, P = 0.003). 
  Of the 1 208 patients, 873 had been examined by at least 
one kind of image examination or with a histological 
biopsy at the time of their diagnosis, while 335 patients 
lacked adequate   information to diagnose or exclude cir-
rhosis. Table 1 lists the demographic characteristics and 
genotype distribution in the 873 chronic HCV patients 
with and without cirrhosis. Based on positive histo-
logical ﬁndings, or an elevated clinical/laboratory data 
combined with at least one positive image, evidence of 
obvious or extensive ﬁbrosis was conﬁrmed in 276 (31.7%) 
individuals..   Between patients with and without cirrho-
sis, statistically signiﬁcant diﬀerences were observed 
with respect to age (P < 0.001), sex (P = 0.011), route of 
transmission (P < 0.001) and HCV genotype distribution 
(P = 0.029). Cirrhosis was present in a large number of 
blood-transmission-related patients (41.8%) (P < 0.001) 
and only in a signiﬁcantly smaller proportion of IDU 199 Hepat Mon. 2012
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patients (15.9%) (P < 0.001). Cirrhosis was also present in 
operation-transmission-related patients (28.3%) and sex-
  transmission-related patients (36.2%), however, statisti-
cally signiﬁcant diﬀerences were not observed between 
patients with or without cirrhosis for these two possible 
routes of transmission. With respect to the HCV subtype 
distribution, cirrhosis was present in a signiﬁcantly 
large proportion of patients with subtype 1b (P < 0.001), 
while for the other subtypes, no signiﬁcant diﬀerence 
was observed between patients with or without cirrhosis 
(P > 0.05). In a multivariate analysis, cirrhosis was found 
to be associated only with the age of the patients (P < 
0.001). 
  4.2. Time Changes o  f Genotypes Distribution and 
Routes of Transmission
      According to the year of HCV infection, we classiﬁed 
the whole population into ﬁve subgroups and a gradual 
upward trend of   patients with chronic hepatitis C (CHC) 
was observed consistent with the time of disease acquisi-
tion.  The number of patients in this hospital-based popu-
lation was 786 (65.1%) over the previous ten years (2002-
2011), while only   353 patients (29.2%) were diagnosed in 
the years from 1992-2001.     As Figure 1 showed, genotype 
1b remained the predominant genotype throughout the 
over 20 year study period.   The proportions of genotypes 
2a and 3a remained stable throughout this time. A sharp 
reduction in the proportion of subjects with genotypes 1 
and a   sharp increase in the proportion of subjects with 
genotype 3b and 6a was observed over this period, and 
statistical analysis was performed to identify the asso-
ciations between the genotypes   and time of infection 
(year) if any. The subtypes 3a and 2a were observed to 
have a statistically non-signiﬁcant correlation with time 
(years) (P > 0.05), while the HCV subtypes 1b, 3b and 6a 
showed signiﬁcantly higher correlations with years (  P < 
0.05).   Similarly, we also observed the changing pattern 
of   the sources of infection during the last 20 years in the 
study population. As Figure 2 shows, a history of trans-
fusion of blood and/or blood products and a history of 
IDU were the main sources of infection. The proportion 
of unknown sources of infection has remained stable 
throughout the study period. For the sex-related CHC, 
no signiﬁcant correlation with time (years) (P > 0.05) 
was observed, however, an increase in this trend could 
be seen with years. A signiﬁcant association between the   
source of infection and the time of the infection (year) 
Cirrhosis Non-cirrhosis P value a
Patients, No. (%)b 276 (31.7) 597 (68.3)
Age c, y, mean ± SD 55.8 ± 11.3 41.6 ± 12.4 < 0.00
Gender 0.011
Male, No. (%)
Female, No. (%)
133 (48.2)
143 (51.8)
343 (57.5)
254 (42.5)
Alcohol drinkers d, No. (%) 37 (13.4) 88 (14.7) 0.601
Route of transmission e, No. (%) < 0.001 f
Blood 
Operation
IDU
SEX 
Unknown 
123 (44.6)
32 (11.6)
43 (15.6)
21(7.6)
57(20.6)
171 (28.6)
81 (13.6)
228 (38.2)
37(6.2)
80(13.4)
< 0.001
< 0.419
< 0.001
0.436
0.007
Genotype distribution, No. (%) 0.029 g
1a
1b
2a
3a
3b
6a
Non-detectable h
-
135 (48.9)
26 (9.4)
29 (10.5.)
44 (15.9)
34 (12.3)
8 (2.9)
1 (1.7)
202 (33.8)
68 (11.4)
89 (16.2)
124 (20.7)
98 (16.4)
15 (2.5)
< 0.001
0.383
0.077
0.092
0.116
Table 1. Demographic Characteristics and Genotype Distribution in Chronic HCV Patients with and without Cirrhosis
a P values were given for the comparison between cirrhosis and non-cirrhosis groups by χ2 tests. 
b Out of all of the 1 208 patients, 873 had been examined by at least one kind of image method or with histological biopsy at the time of diagnosis. Based 
on positive histological ﬁndings or an elevated clinical/laboratory data level, combined with at least one positive image result, 276 individuals had evi-
dence of obvious cirrhosis or extensive ﬁbrosis. 
c In a multivariate analysis, the age of the patients was the only factor associated with the presence of cirrhosis (P < 0.001). 
d Drinker, was deﬁned as alcohol consumption of ≥ 40 g/week for men and ≥ 20 g/week for women, which included occasional drinkers and daily drink-
ers. 
e Blood, patients with a history of transfusion blood or blood products; Operation, patients with a history of invasive operation; IDU, patients with a 
history of IDU; Sex, patients with a history of promiscuity and unsafe sex; Unknown, patients where the source of infection was unclear and unknown.
f P values were given by 2×5 table chi-square between cirrhosis and non-cirrhosis groups.
g P values were given by 2×7 table chi-square between cirrhosis and non-cirrhosis groups.
h Non-detectable, patients whose HCV genotype could not be identiﬁed.200 Hepat Mon. 2012
Yan Z et al. Clinical Epidemiology Switch of HCV Infection
Subtype (n) Potential Route of Infection, No. (%) Total, No.
Blood a 
(n = 406)
Operation a 
(n = 144)
IDU a 
(n = 352)
Sex a 
(n = 96)
Unknown a
(n = 210)
1a 4 (1.0) 1 (0.7) 1 (0.3) 1 (1.0) 2 (1.0) 9
1b 208 (51.2) 64 (44.4) 54 (15.3) 31 (32.3) 41 (19.5) 398
2a 67 (16.5) 23 (16.0) 12 (3.4) 5 (5.2) 19 (9.0) 126
3a 19 (4.7) 10 (6.9) 52 (14.7) 7 (7.3) 67 (31.9) 155
3b 48 (11.8) 22 (15.3) 101 (28.7) 33 (34.4) 24 (11.4) 228
6a 43 (10.6) 18 (12.5) 123 (34.9) 17 (17.7) 17 (8.1) 218
6k 3 (0.7) - - - - 3
Non-detectable a 14 (3.4) 6 (4.2) 9 (2.6) 2 (2.1) 40 (19.1) 71
a Blood, patients with a history of transfusion blood or blood production; Operation, patients with a history of invasive operation; IDU, patients with a 
history of IDU; Sex, patients with a history of promiscuity and unsafe sex; Unknown, patients where the source of infection was unclear and unknown; 
Non-detectable, patients with a HCV genotype that could not be identiﬁed.
 
Table 3. HCV Genotype Distribution According to Route of Infection
Figure 1. Changing Pattern of HCV Genotypes during the Past 20 Years Figure 2. Changes of Possible Mode of HCV Transmission during the Past 
20 Years
was observed. A signiﬁcant reduction in transfusion-re-
lated and operation-related  CHC was observed over time. 
On the contrary there was a dramatic increase in IDU re-
lated hepatitis C, mainly after 1997 (P ≤ 0.001).
4.3. Association of genotypes with the risk factors
 Table  2 translates the age wise distribution of the diﬀer-
ent genotypes observed in the current study. The highest 
Genotype Age Group, No. (%) Total, No.
≤ 20, y 
(n = 63)
21-30, y 
(n = 244)
31-40, y 
(n = 446)
41-50, y 
(n = 257)
51-60, y 
(n = 132)
≥ 61, y 
(n = 69)
1a 0 (0) 2 (0.82) 6 (1.35) 1 (0.39) 0 (0) 0 (0) 9
1b 26 (41.3) 46 (18.9) 89 (19.9) 119 (46.9) 77 (58.3) 41 (59.4) 398
2a 4 (6.3) 21 (8.6) 36 (8.1) 36 (14.2) 20 (15.2) 9 (13.1) 126
3a 10 (15.9) 56 (22.9) 57 (12.8) 22 (8.7) 7 (5.3) 3 (4.35) 155
3b 9 (14.3) 56 (22.9) 108 (24.2) 36 (14.2) 12 (9.1) 7 (10.1) 228
6a 10 (15.9) 51 (20.9) 121 (27.1) 22 (8.7) 9 (6.8) 5 (7.25) 218
6k - - 1 (0.22) 1 (0.39) 1 (0.76) - 3
Non-detectable a 4 (6.3) 12 (4.9) 28 (6.3) 17 (6.7) 6 (4.55) 4 (5.79) 71
Table 2. HCV Genotypes and Risk Factors Distribution Among 1 208 Chronic Hepatitis C Patients According to Age Group
a Patients who had a HCV genotype that could not be identiﬁed.
percentages (36.9%) were in the age group 31–40 years. 
The second most abundant age group of patients with 
all genotypes was in the 41–50 years age group with the 
occurrence of 21.3% followed by the 21–30 years group 
with 20.2%, 10.9% in the 51–60 years age group, 5.7% in the 
≥ 61 years age group and 5.2% in ≤ 20 years age group.   A 
notable variation in the distribution of HCV subtypes in 
the diﬀerent age groups was observed (P < 0.001). Sub-
types 3a, 3b, and 6a were detected in 22.9%, 22.9%, and 201 Hepat Mon. 2012
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20.9% of patients aged 21–30 years, respectively. On the 
other hand, subtypes 1b and 2a were present in only 18.9% 
and 8.62% of cases respectively in the same age group. 
In individuals 31–40 years old,   subtypes 3b (24.2%), and 
6a (27.1%) were also statistically more prevalent than in 
genotype subtypes 1b (19.9%), 2a (14.2%) and 3a (8.7%). In 
the next group (41–50 years old), HCV subtypes 1b, 2a and 
3b were found predominantly (46.9%, 14.2% and 14.2%, 
respectively), while patients with subtypes 3a, and 6a 
were relatively rare (8.7%). In the last two groups (51–60 
and older than 60 years), subtypes 1b and 2a were statisti-
cally predominant, accounting respectively for 73.5% and 
72.5% of all infections observed. Among patients with a 
genotype which could not be identiﬁed, the frequency 
of the diﬀerent age groups ﬂuctuated between the 4-7% 
range and no signiﬁcant diﬀerence was found. Figure 3 
also indicates that subtype 1b   (21.38%   vs. 52.09%) and 2a 
(8.11% vs. 14.29%) were less common in patients <40 years 
of age,   than in those ≥ 40 years old (P < 0.05), whereas,   
in genotype 3a (16.03 %   vs. 7.03%), 3b   (22.97% vs. 12.09%) 
and 6a (24.17% vs. 7.91%) these were much more common 
in patients < 40 years old than in those ≥ 40 years old 
and genotype 6a was less common in patients ≥ 40 years 
old ( P < 0.001). Table 3 depicts the distribution of the HCV 
genotype/subtype in the diﬀerent risk groups. A   signiﬁ-
cant diﬀerence (P < 0.001) in the HCV genotype distribu-
tion, according to the potential route of infection,   was 
observed.     Subtype 1b was found more frequently   among 
51.2%   patients with a history of blood transfusion and 
44.4% of patients with a history of invasive operation and 
medical procedure，while this occurred signiﬁcantly 
less frequently in the IDU group (1 5.3%).    Additionally, sub-
types 1b and 2a were also predominantly observed more 
frequently among 44.4% and 16.0%   patients respectively 
with a history of invasive operation. In contrast, subtypes 
  3b and 6a constituted the majority of HCV infections in 
drug users   (28.7% and 34.9%, respectively), occurring sig-
niﬁcantly more frequently than HCV infection caused by 
a transfusion of blood or blood products (P < 0.05). Sub-
types 3b (34.4%) and 1b (32.3%) were observed more often 
in   patients with a history of promiscuity and unsafe sex 
than in other subtypes with this source of infection. Sub-
type 3a, 1b and the non-detectable group were found in 
31.9%, 19.5 and 19.1% in patients with unknown sources of 
infection, respectively. 
5. Discussion
    In our study, we observed the clinical epidemiological 
characteristics and substantial changes in genotype dis-
tribution in a very large number of patients infected with 
chronic HCV infections over the last 20 years in south-
west China.   We also analyzed the association between 
the distribution of genotypes and certain potential risk 
factors. According to our data, the relative prevalence of 
genotypes 3a, 3b and 6a has increased signiﬁcantly, and 
that of genotypes 1b and 2a has declined considerably 
in the last 20 years in southwest China.   This shift in dis-
tribution was mainly correlated to changes in   the mode 
of HCV transmission, gender and time of the HCV infec-
tion acquisition. To the best of our knowledge no other 
study is available from this region consisting of such a 
large number of patient’s HCV genotypes/subtypes and 
the changing patterns seen over time in these frequen-
cies.   The ﬁrst important ﬁnding of the current study is 
the   observation that the prevalence frequencies of HCV 
genotypes, particularly the subtypes, has changed over 
the last 20 years in southwest China. Unfortunately,   the 
  prevalence of   HCV infections, especially, the prevalence 
of HCV infection with genotype 3 and 6, appears to show a 
rising trend. One of the possible reasons for this increase 
is an increase in the chances of contracting an infection 
with an increase in personnel exchanges. Another impor-
tant reason for this increase is the enhanced awareness 
of patient care with the improvement of living stand-
ards, so, we are better equipped to detect these cases in 
our hospital-based population. One item of good news is 
that the frequency of the HCV subtype 1b decreased from 
58.6% before 1992 to 25% in the previous ﬁve years, as   the 
sub-genotype 1b is considered to be a poor-responder to 
anti-viral therapies when compared to other genotypes 
(3).   More good news is that the proportion of patients 
with genotype 2a has gradually decreased and after 2008 
only a few cases with this genotype (4.3%) were seen and 
it has almost been eradicated from southwest China. 
This decrease in the frequency of sub-genotypes 1b and 
2a is   multifactorial. Firstly, these genotypes are most-
ly spread through the general route of; major/minor 
transfusion of blood and/or blood products, operations, 
surgeries and dental procedures. Due to awareness pro-
grams at the public level, sterilized surgical procedures 
and equipment are now used for these procedures and 
that may be an important reason in limiting its further 
spread. Secondly, a highly probable reason for the com-
plete eradication of genotype 2a may be due to the high 
sustained virological response rates seen for this par-
ticular genotype (36). The results of a systematic review 
of HCV epidemiology in Asia, Australia and Egypt cor-
responds well with our observations (7). Studies from 
Europe have also shown a decrease in genotype1b and 
Figure 3. Distribution of HCV Genotype in the Subgroups of > 40 years 
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2a and the emergence of genotype 3 (14-16). In a previous 
study conducted in southwest China, although it evalu-
ated the relative frequencies of HCV genotypes in only 
367 unselected patients, it also showed a similar trend in 
genotype distribution (34). 
The second interesting   ﬁnding of the current study is 
the observation that the mode of HCV transmission has 
also changed in the last 20 years in southwest China. A 
history of blood and/or blood products transfusion re-
mained the main source of infection throughout this 
period of time   where the rate gradually decreased from 
47.8% to 27.6% in this region. It is worth mentioning that 
the risk of transfusion-related HCV-hepatitis progres-
sively declined, possibly due to the implementation of 
an all-volunteer blood donor system and the eﬀective 
virus-inactivation procedures for blood derivatives after 
1997. On the other hand there was a   dramatic increase 
in IDU related hepatitis C, mainly after 1997 when its 
rate gradually increased from 14.5% to 29.1%. T  he key rea-
son for this dramatic increase in IDU related hepatitis C 
may be due to the fact that most regions of   southwest 
China are connected to southeast Asia which is one of 
the world’s most important opium planting and drug 
producing bases, and southwest China has been an im-
portant transit area for the smuggling of drugs to other 
regions of China (27).   The third ﬁnding is the association 
between the genotypes distribution and certain poten-
tial risk factors, such as gender and age of HCV infection 
acquisition. In this study, there was a variation of HCV 
genotypes among male and female patients. Subtypes 
3a, 3b and 6a were found more frequently in men than 
in women, while subtypes 1b and 2a were more frequent 
in women than in men. Previous studies on the associa-
tion of gender with speciﬁc HCV genotypes were found 
to be equivocal. In Luxembourg, the prevalence of HCV 
genotype 3 was found to be signiﬁcantly associated with 
males while genotype 2 was more frequent in females 
(37). However, no signiﬁcant diﬀerence was found in Pa-
kistan as the distributions of HCV genotypes were similar 
in both male and female patients (38, 39). Unlike a recent 
study (40), we were able to ﬁnd an association between 
HCV genotypes/subtypes and age, where a predominant 
prevalence of HCV genotypes 3 and 6 was seen in young-
er age patients. However, it should be noted that age at 
HCV infection, although found to be associated with the 
changes in HCV genotypes’ distribution over time in 
univariable analysis, its signiﬁcance did not persist in 
multivariable analysis. This is because, the younger HCV 
positive patients belonged to the group of IDU acquired 
infection, while the older ones belonged to the blood 
transfusion acquired infection group. These results are 
consistent with other reports from diﬀerent geographi-
cal regions of the world (16, 17, 39, 41, 42). 
Most importantly, a signiﬁcant diﬀerence in HCV gen-
otype distribution by the source of infection was ob-
served. Subtype 1b was found more frequently among 
patients with a history of blood transfusion and invasive 
operation, while subtypes 3b and 6a were more frequent 
among patients infected via IDU. This observation might 
reﬂect a tendency for a gradual change in the spectrum 
of HCV variants circulating in the southwest China popu-
lation. There are two possible explanations: the ﬁrst is 
that there are signiﬁcantly more IDUs among younger 
patients compared to the older group of patients, and 
genotypes 3 and 6 are more frequent among IDUs than 
in other patients. However, the altered genotype pat-
terns reported here are also found among patients who 
only have a history of transfusion, or whose modes of 
HCV acquisition are unclear. Logistic regression analysis, 
with adjustment for gender and diﬀerent modes of HCV 
acquisition, also demonstrated that the age of the in-
fected subjects was a direct explanatory variable for HCV 
genotype distribution. Thus, the observed shift in HCV 
genotype distribution cannot be attributed exclusively 
to changes in the epidemiological relevance of diﬀerent 
known risk factors for HCV transmission. The second pos-
sible reason is that those infected via IDU were infected 
with ‘imported’ genotypes that they then gradually trans-
mitted to the non-IDU populations through blood dona-
tion or other routes. It can perhaps be presumed that 
the diﬀerent distribution of HCV genotypes observed in 
the IDU population is due to an increase of “imported” 
genotypes (3 and 6). Therefore, younger people have a 
greater chance of being infected with the “imported” 
genotypes than older people, which is in agreement with 
the signiﬁcantly higher frequency of genotypes 3 and 6 
among patients infected after 1997 than in those infected 
before 1997, as found in the present study. Furthermore, 
through the evaluation of patients with a known geno-
type and a deﬁned duration of HCV infection, we have 
recorded a signiﬁcant increase in the proportion of pa-
tients infected with genotype 3b and 6a mainly after the 
2000’s and a decline in post-transfusion HCV infections 
over time. Therefore, blood safety and improvement in 
infection control practices have paved the way for IDU to 
become, not only the main risk factor for HCV transmis-
sion, but also to alter the genotype distribution among 
patients with HCV hepatitis. As a retrospective study per-
formed only in one centre, some limitations are diﬃcult 
to avoid. First, although our patients came from various 
provinces and municipalities in southwest China, our 
hospital-based population may not be representative 
of the general population in southwest China. Second, 
the retrospective design of the current study may have 
led to selection bias. Our large number of participating 
patients, the inclusion of all patients followed-up dur-
ing the study period regardless of their treatment or ﬁ-
nal clinical outcome, and the exclusion of patients with 
missing crucial data may partly overcome the limitations 
of the design. Third, the possible transmission route was 
unknown for a substantial number of the study popula-
tion. Our analysis revealed that the demographic and 
clinical proﬁle of those patients was similar to that of 
patients infected through blood transfusions. There-
fore, it is most likely, that these patients represent old 
infections. However, taking into consideration that their 203 Hepat Mon. 2012
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date of infection is unknown, this hypothesis cannot be 
tested. In addition, the genotypes of 5% of our sample 
were unable to be classiﬁed with the present genotyping 
system and the proportion of non-detectable genotypes 
remained stable throughout the study period. These may 
include new subtypes, which may be beyond the scope of 
the current genotyping method used in this study.
In conclusion, our results show that the epidemiol-
ogy of HCV infection is changing in southwest China. 
With the implementation of mandatory HCV screening 
of blood and blood products, IDU has accounted for the 
vast majority of all new HCV infections. Due to the rising 
prevalence of HCV among “new IDUs”, those risk behav-
iors should become the focus of interventions for the 
prevention of infectious diseases in the drug using popu-
lation. Furthermore, there is a need for more systematic 
treatment of hepatitis C for drug users. 
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